Advanced Biomed Inc. is executing a strategic pivot from life sciences to artificial intelligence development. The company completed the acquisition of 100% of Acellent Technologies (Hong Kong) Co. Limited. Consideration for the acquisition involved the issuance of 270,000 shares of common stock valued at $4.00 per share, totaling $1,080,000. Mr. Xiaomin Chen has been appointed as the new CEO, director, and Chairman of the Board, effective April 28, 2026. Former CEO Yi Lu has stepped down as part of a mutual separation agreement, receiving 39,999 shares of common stock as severance.